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Abstract
Introduction Selective and non-selective cyclo-oxygen-
ase (COX) inhibitors impair bone healing by inhibiting
prostaglandin synthesis. The purpose of this study was to
evaluate the long-term eVect of parecoxib, a selective
COX-2 inhibitor, on bone healing in rats, when it is applied
in a pattern similar to clinical treatment patterns, that is, in a
high dose and for a short period after bone fracture.
Method Closed non-displaced mid-diaphyseal fractures in
the middle of the left femoral shaft were generated in each
animal. In the study group, parecoxib sodium (1.06 mg/kg)
was administered intra-peritoneally every day for 7 days. In
the control group, normal saline was administered intra-
peritoneally every day for 7 days. In both groups fracture
healing (bone union and callus formation) was evaluated
with X-rays 28 and 42 days after surgery.
Results Bone healing was lower in the study group (60 vs.
80% in the control group 28 days after fracture and 80 vs.
90% 42 days after fracture) but this diVerence was not sta-
tistically signiWcant (P > 0.05).
Conclusion Parecoxib does not have a signiWcant long-
term eVect on bone healing in rats, when it is administered
in a high dose and for a short period after bone fracture.
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Abbreviations
COX Cyclo-oxygenase
NSAIDs Non-steroidal anti-inXammatory drugs
Introduction
Non-steroidal anti-inXammatory drugs (NSAIDs) are used
widely as analgesics in the treatment of acute post-operative
and traumatic pain in orthopedics. NSAIDs act on cyclo-
oxygenase (COX) and inhibit prostaglandin synthesis from
arachidonic acid. Prostaglandins can stimulate bone forma-
tion as well as bone resorption, and shift the critical balance
of bone resorption and formation towards formation [1, 2].
By inhibiting prostaglandin synthesis, non-selective
COX inhibitors can delay and decrease rates of fracture
healing in treated animals [3–6]. As COX-2 plays a crucial
role in fracture healing [1, 2], selective COX-2 inhibitors
have also demonstrated inhibitory eVects on bone healing.
But data obtained from studies with treated animals are
rather controversial. Some studies have shown that selec-
tive COX-2 inhibitors have an inhibitory eVect on bone
healing, similar to that of non-selective COX inhibitors [1,
7, 8]. There are also studies where COX-2 inhibitors appear
to have a higher [9, 10] or lower or insigniWcant eVect on
bone healing [6, 11–13]. These controversies can be attrib-
uted to their transient eVect on COX-2 inhibition, which is
also related to dosage, gender and duration of therapy.
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may play an important clinical role in bone rehabilitation
post-operatively or after fractures, because of their wide use
as analgesics in orthopedics. Because of their potentially
negative eVect on bone healing, several authors recommend
great caution in the use of COX inhibitors and suggest to be
used only for a short period after fracture or surgery [6, 14–
20]. On the other hand, pain relief is also very important in
orthopedics and it may be more substantial in achieving
quick rehabilitation than real strength of bone, as it may
facilitate earlier mobilization, while supporting material
can be used for movement during the Wrst post-operative
days. From a clinical point of view, what seems to be more
important with the use of COX inhibitors post-operatively
is not their transient inhibition on bone healing but the
reversibility of this inhibition and their long-term eVects on
bone healing and rehabilitation.
The aim of this study was to investigate radiographically
the long-term eVect of parecoxib, a selective COX-2 inhibi-
tor, on fracture healing in rats, when it is administered in a
pattern similar to the recommended clinical treatment pat-
terns, that is, for a short period after fracture. The dose of
parecoxib used in this study was more than threefold higher
than the dose required for establishing inhibition of COX-2
[20] but quite close to doses used in clinical practice. In
fact, this dose was slightly higher than the average recom-
mended therapeutic dosages in humans, but less than two-
fold the highest recommended dose in clinical practice.
Materials and methods
Animals
A total of 40 adult male Albino Wistar rats, 12-week-old,
weighing 250–350 g (mean: 295, SD: 32) were used in this
study. The animals were obtained from the breeding colony
and were housed under standard laboratory conditions
(temperature 22 § 2°C, humidity 50–60% and 12-h light–
dark cycle). All animals were housed individually in trans-
parent plastic cages (24 £ 13.5 £ 13 cm) with food and
fresh tab water available ad libitum. Food was the standard
rat chow, containing 1.1% calcium and 0.9% total phospho-
rus. The animals were divided in two groups, before opera-
tion: study group (20 animals) and control group (20
animals). The person who performed the operations was
blinded to the treatment groups.
Drugs
Parecoxib sodium (dr.pd.inj. 20 mg per vial), cefuroxime
sodium (dr.pd.inj. 250 mg per vial) and normal saline
(sodium chloride inj.so.inf. 0.9% W/V) were obtained com-
mercially. Drugs were supplied in the form of an intra-peri-
toneal solution.
Surgical procedure
Animal research was conducted in conformity with the rec-
ommended guidelines, and the standard protocol described
by Bonnarens and Einhorn [21] was used for generation of
closed transverse mid-diaphyseal femoral fractures. In
brief, fractures were generated by external blunt trauma to
the femur after its stabilization by insertion of an intramed-
ullary pin.
Rats were anesthetized in saturation conditions with
ether. They were weighed in order to determine the dosage
of the administered drugs. Appropriate depth and duration
of anesthesia was achieved by intraperitoneal injections of
cetamine 87 mg/kgBW and xylazine 13 mg/kgBW [22].
After conWrming anesthesia, by estimating the retinal
reXex, the overlying skin of the left femora was shaved and
swabbed with povidone iodine for disinfection, and was
draped. Through a median parapatellar skin incision, a 20-
gauge needle was used to ream the femoral medullary
canal, through patellar tendon at the intracondular entry
point. A retrograde insertion of a 0.25-mm Kirschner wire
was used for intramedullary Wxation. The proximal end of
the wire was isolated, cut, buried and Wxed in the medullary
canal. The incision was closed, and a closed mid-diaphy-
seal fracture was generated using a three-point bending
apparatus, as described by Bonnarens and Einhorn [21].
The production of standard closed mid-diaphyseal fractures
was conWrmed by X-rays. The rats were monitored daily for
signs of pain or distress.
Principles of laboratory animal care were followed, and
Institutional guidelines for the care and treatment of labora-
tory animals were kept. The protocol for the use of animals
was approved by the Local Ethics Committee on Animal
Research.
Drug administration
In the study group parecoxib sodium (1.06 mg/kg) was
administered intra-peritoneally, immediately after the surgi-
cal procedure and fracture, and once daily for 7 days. In the
control group normal saline was administered intra-peritone-
ally, immediately after the surgical procedure and once daily
for 7 days. The animals were treated with an intraperitoneal
injection of cefuroxime in the prophylactic dose of 20 mg/kg,
2 h preoperatively and once a day for the next 2 days [23].
Imaging
Plain Wlm was chosen to conWrm bone fractures and proper
intramedullar Wxation and to assess bone healing, as it is a123
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and bone formation and healing; it is commonly used in
experimental studies [2, 7] but it is also the most commonly
used diagnostic method in clinical practice, on which usu-
ally clinical decisions are taken and rely.
Anteroposterior and lateral radiographs of all treated
femora were performed immediately after fracture and at
the time period of 28 and 42 days after fracture. In order to
estimate evidence of delayed healing, radiographs were
analyzed with respect to (1) callus formation and maturity
and (2) bridging bone formation on the four cortices as seen
on anteroposterior and lateral radiographs of femora in all
groups of animals.
All plain Wlms were interpreted by two independent radi-
ologists blinded to the treatment group. The mean of dupli-
cate scores was used for statistical analysis.
Statistical analysis
The student’s t test was used to determine the statistical
diVerence between the study and the control group. Statisti-
cal diVerence was inferred at P < 0.05.
Results
X-rays performed immediately after surgery and fracture
production, showed that closed transverse mid-diaphyseal
fractures of the left femur were generated in all animals
(Fig. 1a).
At the time period of 28 and 42 days after surgery, anter-
oposterior and lateral views were performed, to assess cal-
lus formation, remodeling and bridging bone formation in
sagittal and coronal planes.
After 28 days of fracture bone healing and bridging cal-
lus formation was conWrmed by X-rays in 12 out of 20
cases (60%) in the study group (Fig. 1b) and in 16 out of 20
cases (80%) in the control group. This diVerence was not
statistically signiWcant (P = 0.176). After 42 days of frac-
ture, bone healing and bridging callus formation was con-
Wrmed by X-rays in 16 out of 20 cases (80%) and in 18 out
of 20 cases (90%), respectively. This diVerence was not sta-
tistically signiWcant (P = 0.389, Table 1).
Discussion
In our study we found that parecoxib, a new selective
COX-2 inhibitor, has only a transient eVect and does not
appear to present a signiWcant long-term eVect on bone
Fig. 1 Radiographic assessment of bone healing of a mid-diaphyseal
fracture in an adult rat immediately after fracture and 28 days after
fracture. Parecoxib sodium (1.06 mg/kg) was administered for 7 days
immediately after fracture. a Radiographic conWrmation of a closed,
non-displaced mid-diaphyseal fracture immediately after production.
Kirschner wire is Wxed in the intramedullary canal. b Radiographic
assessment of bone healing after 28 days. Callus formation, remodel-
ing and bridging bone formation is observed
Table 1 Bone healing of mid-diaphyseal fractures in adult rats 28 and
42 days after fracture
a In the study group (n = 20) parecoxib sodium (1.06 mg/kg) was
administered for 7 days immediately after fracture
b In the control group (n = 20) normal saline was administered for
7 days immediately after fracture
c A delay in bone healing was observed in the study group but the
diVerence in bone healing between the study and the control group was
not statistically signiWcant (P > 0.05)
Bone healing
28 days after 
fracture
42 days after 
fracture
Study groupa (%) 60% 80%
Control groupb (%) 80% 90%
DiVerencec P = 0.176 P = 0.389123
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high dose and for a short period after fracture.
Cyclo-oxygenase inhibitors play an important role in
bone healing and nociception, as they are implicated in
prostaglandin synthesis. In principle, injury causes neuro-
nal discharge of nociceptors. At the site of injury, a mixture
of inXammatory substances is released and ampliWes the
nociceptive input by activating dormant neurons and
increasing peripheral excitability [24]. Serotonin, hista-
mine, bradycinin, cytokines, growth factors and prostaglan-
dins are important components of this inXammatory
mixture and contribute signiWcantly to peripheral neuronal
sensitization [25–27].
Bone healing is initiated by this inXammatory mixture.
Two main types of cells are responsible for bone renewal:
osteoblasts, involved in bone formation and osteoclasts,
involved in bone resorption. The function of these cells is
inXuenced by hormones, vitamin D and cytokines. Prosta-
glandins are produced by osteoblasts and act locally to
modulate bone metabolism. Prostaglandins can stimulate
bone formation as well as resorption. PGE2 plays a substan-
tial role and shifts the critical balance of bone resorption
and formation towards formation [1, 2].
Several studies have shown delayed and decreased rates
of fracture healing in animals treated with non-selective
COX inhibitors, like aspirin, indomethacin, naproxen, dic-
lofenac and ketorolac [3–6, 28–32]. Nevertheless, research
on selective COX-2 inhibitors has demonstrated controver-
sial eVects on bone healing: Etodolac was shown to possess
an inhibitory eVect on bone healing [7]. Celecoxib was
found either to possess an inhibitory eVect [1] or to possess
a diminished or no inhibitory eVect [11–13]. Studies on
rofecoxib showed an inhibitory eVect [1, 8], which was
sometimes higher [9] and other times much lower than that
observed with non-selective COX inhibitors [12]. Valdec-
oxib was found to have a higher inhibitory eVect on bone
healing, which was transient [10]. But parecoxib, which is a
prodrug of valdecoxib showed a lower inhibitory eVect on
bone healing [6, 16], which was also gender dependent: it
was insigniWcant in male and signiWcant in female rats [16].
By inhibiting COX-2, which plays the most important role
in bone formation, selective COX-2 inhibitors must present a
more potent inhibition on fracture healing than non-selective
COX inhibitors. This action has been demonstrated in previ-
ous works [9, 10] but it was also shown that it can be
reversed and have minor and non important eVects in a long-
term period [10, 15]. It seems also to be dependent on dosage
and duration of treatment [6, 10, 14, 16]. Meunier and
Aspenberg [16], working with Sprague–Dawley rats showed
that it is also gender dependent, and they attributed this gen-
der-speciWc diVerence to diVerent rates of metabolism. It is
obvious that such diVerences are also species dependent and
it is probable that they may also be race dependent.
In our study we used albino Wistar rats and observed
that parecoxib, used in a high dose and for a short period
after surgery, presents a transient delay but has not a sig-
niWcant long-term eVect on bone healing. These Wndings
are in agreement with previous works with parecoxib stud-
ied in Sprague–Dawley rats [6, 16], although diVerent pat-
terns of treatment and diVerent approaches of interpreting
data were used, and in one study [16] a diVerent model of
studying fracture healing was used. As parecoxib is a pro-
drug of valdecoxib, our Wndings are also in agreement with
a previous work studying valdecoxib on Sprague–Dawley
rats [10].
Currently there are no established dosage recommenda-
tions for studies in animals. And data obtained from studies
in animals cannot be used directly to interpret the eVect of
drugs on human beings, as there are many species-depen-
dent diVerences. But we believe that despite species related
diVerences, it would be useful if dosages used in animals
were close to dosages used in humans. In our study, we
selected to use a dose higher than the dose required for
establishing inhibition of COX-2 [20] but quite close to
doses used in clinical practice. Although slightly higher
than the average recommended therapeutic dosages in
humans, this dose is less than twofold the highest recom-
mended dose in clinical practice. To our knowledge, this is
the Wrst experimental work on parecoxib studied in rats, in
which a treatment pattern close to current recommended
clinical treatment patterns (in respect to dosage and dura-
tion of therapy) was used, and in which long-term eVects of
a short treatment were studied. In our study we have not
investigated the initial inhibition of COX-2, culminating in
initial inhibition and delay of bone repair, as this was out of
the scope of this work and as this action is not only
expected theoretically but is also well documented in previ-
ous works [10, 20].
Bone fracture is a common injury, which deteriorates
patients’ health directly and indirectly, when rehabilitation
is not optimum. In order to achieve the best possible reha-
bilitation, patients are encouraged for prompt mobilization
but sometimes this advice is not kept because of pain. COX
inhibitors are the most common pain relievers in these
cases but they have the disadvantage of inhibiting and
delaying bone strength and bone repair. Selective COX-2
inhibitors have been used more frequently the last years, as
they exhibit analgesic and anti-inXammatory eVects
comparable to non-selective COX inhibitors [14, 33], while
reducing the prevalence of adverse eVects such as gastroin-
testinal bleeding and platelet abnormalities [34, 35]. But
selective COX-2 inhibitors possess a potentially higher risk
for inhibiting bone healing and should be used with great
caution [6, 14, 17–19]. When they are used as pain reliev-
ers, and to facilitate early mobilization during the Wrst
post-operative days, patients should be advised to be very123
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strength is reduced by these drugs [6, 16]; they should also
be aware that they must make a short use of these drugs and
stop pain relievers as soon as possible. In fact, further
research is necessary, with additional experimental studies
in animals and—as data on human beings are very lim-
ited—clinical trials should also be carried out, to make
clear that the inhibitory action of NSAIDs on bone healing
is really transient and has no irreversible eVects in bone
strength and bone repair.
In conclusion, our study is the Wrst experimental study
of parecoxib in rats, in which a treatment pattern close to
current clinical treatment patterns was used, and in which
the long-term eVects of a short treatment were studied.
According to our results, parecoxib, given in a high dose
and for a short duration after bone trauma, seems to have a
transient inhibitory eVect on bone healing in rats but the
long-term eVects seem not to be signiWcant. Further
research is necessary to establish that its inhibitory action
in bone repair is also reversible in humans, and to prove
its safety when used as analgesic in bone fractures and for
the relief of post traumatic and postoperative pain in
orthopedics.
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